Top 3 drug approvals in oncology: August 2021
Over the past month, several oncology drugs have been newly approved; in this piece we provide you with the key facts to keep you up-to-date with the industry news. Highlights include the approval of Opdivo® plus Yervoy® by the Medicines and Healthcare products Regulatory Agency (MHRA) and Verzenios® with Faslodex® by NICE in the UK. Opdivo (nivolumab) plus Yervoy (ipilimumab) Approved: 5 August 2021 Company: Bristol Myers Squibb (NY, USA) Indication: Inoperable pleural mesothelioma “The approval of nivolumab plus ipilimumab is the first drug approval for mesothelioma since 2004 and will potentially improve survival expectations in these patients,” commented Sanjay...